Merit Medical Systems, Inc. (NASDAQ:MMSI - Get Free Report) CFO Raul Jr. Parra sold 5,361 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $103.58, for a total value of $555,292.38. Following the completion of the sale, the chief financial officer now owns 24,201 shares in the company, valued at approximately $2,506,739.58. The trade was a 18.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Raul Jr. Parra also recently made the following trade(s):
- On Friday, February 28th, Raul Jr. Parra sold 12,451 shares of Merit Medical Systems stock. The shares were sold at an average price of $98.81, for a total value of $1,230,283.31.
Merit Medical Systems Trading Down 2.8 %
Shares of Merit Medical Systems stock traded down $2.84 during mid-day trading on Monday, hitting $97.11. 889,537 shares of the stock were exchanged, compared to its average volume of 589,470. The company has a 50-day simple moving average of $103.35 and a 200 day simple moving average of $100.49. Merit Medical Systems, Inc. has a twelve month low of $70.70 and a twelve month high of $111.45. The stock has a market capitalization of $5.71 billion, a price-to-earnings ratio of 47.60, a price-to-earnings-growth ratio of 2.34 and a beta of 0.91. The company has a current ratio of 5.36, a quick ratio of 3.82 and a debt-to-equity ratio of 0.57.
Wall Street Analysts Forecast Growth
MMSI has been the subject of a number of research reports. Wells Fargo & Company reduced their price objective on Merit Medical Systems from $120.00 to $117.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Needham & Company LLC dropped their price objective on shares of Merit Medical Systems from $122.00 to $116.00 and set a "buy" rating on the stock in a research note on Wednesday, February 26th. Piper Sandler reiterated an "overweight" rating and set a $116.00 target price (up previously from $114.00) on shares of Merit Medical Systems in a research note on Wednesday, January 29th. Barrington Research lowered their target price on Merit Medical Systems from $115.00 to $111.00 and set an "outperform" rating on the stock in a research note on Wednesday, February 26th. Finally, Raymond James upped their price target on Merit Medical Systems from $105.00 to $110.00 and gave the stock an "outperform" rating in a research note on Tuesday, December 31st. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Merit Medical Systems presently has an average rating of "Moderate Buy" and an average price target of $110.78.
View Our Latest Stock Analysis on MMSI
Institutional Investors Weigh In On Merit Medical Systems
A number of institutional investors have recently added to or reduced their stakes in the company. Peak Retirement Planning Inc. acquired a new position in shares of Merit Medical Systems in the fourth quarter worth about $875,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Merit Medical Systems by 17.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 165,344 shares of the medical instruments supplier's stock valued at $15,992,000 after buying an additional 24,528 shares in the last quarter. iSAM Funds UK Ltd acquired a new stake in Merit Medical Systems in the fourth quarter worth approximately $424,000. Virtus Investment Advisers Inc. raised its position in Merit Medical Systems by 45.7% in the fourth quarter. Virtus Investment Advisers Inc. now owns 11,192 shares of the medical instruments supplier's stock worth $1,082,000 after acquiring an additional 3,513 shares in the last quarter. Finally, Tidal Investments LLC lifted its stake in Merit Medical Systems by 3,197.9% during the fourth quarter. Tidal Investments LLC now owns 342,912 shares of the medical instruments supplier's stock valued at $33,166,000 after purchasing an additional 332,514 shares during the last quarter. Hedge funds and other institutional investors own 99.66% of the company's stock.
About Merit Medical Systems
(
Get Free Report)
Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.
See Also
Before you consider Merit Medical Systems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merit Medical Systems wasn't on the list.
While Merit Medical Systems currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
